Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Securities in F&O Ban:
RBL Bank, Oracle Financial Services Software, Angel One and HFCL shares are banned from F&O trading on 18 September 2025.
Stocks to Watch:
Biocon arm, Biocon Biologics, a has received USFDA approval for Bosaya and Aukelso. Bosaya is indicated for the treatment of postmenopausal women with osteoporosis, while Aukelso is approved for the prevention of skeletal-related events in patients with multiple myeloma.
Cochin Shipyard announced that it has signed an agreement with ONGC for dry dock/major lay-up repairs of a jack-up rig. The estimated contract value is around Rs 200 crore.
Muthoot Microfin announced that its board has approved raising up to Rs 75 crore through the issuance of up to 7,500 listed, rated, senior, secured, transferable, redeemable, non-convertible debentures (NCDs) on a private placement basis.
Lodha Developers informed that Rajendra Lodha has resigned as a director of the company. Based on information gathered through internal inquiries, the matter has been referred to the appropriate authorities for investigation. At the company’s request, Rajendra Lodha resigned from all positions within the organization on 17 August 2025.
Rashtriya Chemicals and Fertilizers (RCF) announced that its board will meet on 25 September 2025 to consider the issuance of NCDs worth Rs 400 crore on a private placement basis.
RailTel Corporation of India announced that it has received an order worth Rs 105.74 crore for the procurement, supply, and installation of smart classrooms from the Bihar Education Body.
Cera Sanitaryware informed that it is currently in the process of divesting its stake in its joint venture partner, Shreeyam Ceramic LLP.
JSW Steel announced that it has signed a definitive agreement to acquire an additional economic interest in M Res NSW for $60 million. This acquisition will increase the company’s economic interest from 66.67% to 83.33%.
Bombay Dyeing & Manufacturing Company announced the appointment of Rohit Santhosh as the chief executive officer of Bombay Realty, effective 18 September, 2025.
Biocon announced the inauguration of its first U.S. manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI).
Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.
The Cranbury facility represents a strategic advancement for the Company's U.S. operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States.
Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Biocon's first U.S. FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy's presence at the inauguration highlights the importance of Biocon's role in fostering innovation, creating job opportunities, and strengthening the U.S. healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future.”
At the conclusion of the inspection, the U.S. FDA issued a Form 483 citing five procedural observations. According to Biocon, these observations are not related to data integrity, systemic non-compliance, or quality oversight issues.
Biocon Biologics has stated that it will submit a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated timeframe and expressed confidence in addressing all observations promptly and effectively.
Importantly, the company confirmed it does not anticipate any impact on the supply of its commercial products.
“Biocon Biologics remains committed to upholding the highest standards of quality and compliance,” the company said in a statement, adding that it continues to work collaboratively with global regulatory agencies to ensure the safety, efficacy, and reliability of its products.
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.
In its latest financial results, Biocon reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite a 15.8% jump in net sales to Rs 3,910.10 crore in Q1 FY26 compared to Q1 FY25.
Shares of Biocon rose 1.68% to Rs 362.90 on the BSE.